Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain-Reference-Cited by-同舟云学术

Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

Published:2024-07-22 Issue:9 Volume:41 Page:3569-3584
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Botana López Manuel^ORCID,Camafort Babkowski Miguel^ORCID,Campuzano Ruiz Raquel,Cebrián Cuenca Ana^ORCID,Gargallo Fernández Manuel^ORCID,David de Paz Héctor^ORCID,Redondo-Antón Jennifer^ORCID,Artime Esther^ORCID,Díaz-Cerezo Silvia^ORCID,Rubio de Santos Miriam^ORCID

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02938-2.pdf

Reference43 articles.

1. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5:444–70. https://doi.org/10.4239/wjd.v5.i4.444.

2. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. https://doi.org/10.1186/s12933-018-0728-6.

3. Cebrián-Cuenca AM, Mata-Cases M, Franch-Nadal J, Mauricio D, Orozco-Beltrán D, Consuegra-Sánchez L. Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population. Eur J Prev Cardiol. 2022;28:e32–4. https://doi.org/10.1093/eurjpc/zwaa073.

4. Artime E, Romera I, Díaz-Cerezo S, Delgado E. Epidemiology and economic burden of cardiovascular disease in patients with type 2 diabetes mellitus in Spain: a systematic review. Diabetes Ther. 2021;12:1631–59. https://doi.org/10.1007/s13300-021-01060-8.

5. Reyes-García R, Moreno-Pérez O, Bellido-Castañeda V, Botana López M, Rodríguez-Hervada AD, Fernández-García D. Abordaje integral de las personas con diabetes tipo 2. Área de Conocimiento de Diabetes de la Sociedad Española de Endocrinología y Nutrición. https://www.seen.es; 2023. Accessed 28 Mar 2023.